Sp119
ESOPHAGUS
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session will have six talks on the indications, limitations, procedural and technical aspects on clinically useful GI physiology tests. The attendees will learn for which patients these test can be of value, and what type of results you can expect and how reliable these are. Furthermore, the attendees will receive information on how to interpret results from these tests.
This session will have six talks on the indications, limitations, procedural and technical aspects on clinically useful GI physiology tests. The attendees will learn for which patients these test can be of value, and what type of results you can expect and how reliable these are. Furthermore, the attendees will receive information on how to interpret results from these tests.
Presenter
Amsterdam UMC, University of Amsterdam
Tracks
Related Products
PANEL DISCUSSION
GERD refractory to standard therapy is a common problem in clinical practice. The causes are multiple and there is a need for a rational evidence based approach to this problem…
DUPILUMAB IMPROVES HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS, REGARDLESS OF PRIOR HISTORY OF ESOPHAGEAL DILATION
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
SCOPE OF THE PROBLEM: DISEASE DEFINITION AND EPIDEMIOLOGY
GERD refractory to standard therapy is a common problem in clinical practice. The causes are multiple and there is a need for a rational evidence based approach to this problem…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
